Screening method
The present invention provides a method of screening for an agent for the treatment of human diabetes mellitus, which comprises administering a test compound to a diabetes mellitus model non-human mammal, and selecting a compound that causes a decrease of not less than 0.5% in a glycated hemoglobin value after administration.
1 . A screening method for an agent for the treatment of human diabetes mellitus, which comprises administering a test compound to a diabetes mellitus model non-human mammal, and selecting a compound that causes a decrease of not less than 0.5% in a glycated hemoglobin value after administration.
2 . The screening method of claim 1 , wherein the non-human mammal is a rodent.
3 . The screening method of claim 2 , wherein the rodent is a rat.
4 . The screening method of claim 1 , wherein the diabetes mellitus model non-human mammal is a Wistar fatty rat.
5 . The screening method of claim 1 , wherein the diabetes mellitus model non-human mammal is a Zucker diabetic fatty rat.
6 . The screening method of claim 1 , wherein after administration is 4 weeks after administration.
7 . The screening method of claim 1 , wherein the agent for the treatment of human diabetes mellitus is a compound that causes a decrease of not less than 0.5% in a hemoglobin A1c value at 12 weeks after administration.
8 . An agent for the treatment of human diabetes mellitus, which is obtained by the screening method of claim 1.